Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
450 participants
OBSERVATIONAL
2022-02-28
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Gut Microbiota and Its Metabolites on the Efficacy of Immunotherapy in Metastatic Colorectal Cancer
NCT06714903
Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy
NCT04333004
Washed Microbiota Transplantation for the Treatment of Oncotherapy-Related Intestinal Complications
NCT04721041
Fecal DNA Methylation Detection for Gastric Cancer
NCT06943807
Gut Microbiota Reconstruction for NSCLC Immunotherapy
NCT05008861
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy group
Healthy people in the community.
Healthy control specimen collection
Collecting blood and feces from healthy population.
Non-Borrmann IV group
Patients with Borrmann types I, II and III gastric cancer.
Non-Borrmann IV patient specimen collection
Collecting blood, feces and gastric cancer tissues from Non-Borrmann IV patients.
Borrmann IV group
Patients with Borrmann type IV gastric cancer.
Borrmann IV patient specimen collection
Collecting blood, feces and gastric cancer tissues from Borrmann IV patients.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Healthy control specimen collection
Collecting blood and feces from healthy population.
Non-Borrmann IV patient specimen collection
Collecting blood, feces and gastric cancer tissues from Non-Borrmann IV patients.
Borrmann IV patient specimen collection
Collecting blood, feces and gastric cancer tissues from Borrmann IV patients.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Borrmann classification of gastric cancer is determined by more than 2 pathologists.
3. Patients with BMI 24-28.
4. Karnofsky (KPS) score \>80.
Exclusion Criteria
2. Patients who complicate with other malignant tumors.
3. Patients who complicate with diabetes, hypertension, heart disease and infectious diseases.
4. Patients who complicate with inflammatory bowel disease or irritable bowel syndrome.
5. Patients with metastasis.
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Liaoning Cancer Hospital & Institute
OTHER
The Second Hospital of Shandong University
OTHER
The General Hospital of Fushun Mining Bureau
UNKNOWN
The fourth People's Hospital of Changzhou
UNKNOWN
The First People's Hospital of Jingzhou
OTHER
First Hospital of China Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kai Li
Deputy Director of surgical Oncology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kai Li, MD
Role: PRINCIPAL_INVESTIGATOR
First Hospital of China Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The fourth People's Hospital of Changzhou
Changzhou, Jiangsu, China
Chaoyang Central Hospital
Chaoyang, Liaoning, China
The General Hospital of Fushun Mining Bureau
Fushun, Liaoning, China
First Hospital of Jinzhou Medical University
Jinzhou, Liaoning, China
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
The Second Hospital of Shandong University
Ji'nan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yan Li
Role: primary
Shigang Guo
Role: primary
Yubin Wang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Metabonomics
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.